Square (SQ) Stock Buy Rating Reaffirmed at KeyBanc; The Price Objective is $55.0000; Cerus (CERS) Has 1.45 Sentiment

April 23, 2018 - By Richard Conner

Square, Inc. (NYSE:SQ) Logo

Cerus Corp (CERS) investors sentiment increased to 1.45 in Q4 2017. It’s up 0.13, from 1.32 in 2017Q3. The ratio is positive, as 45 hedge funds started new and increased equity positions, while 31 reduced and sold their positions in Cerus Corp. The hedge funds in our database now own: 58.96 million shares, up from 57.26 million shares in 2017Q3. Also, the number of hedge funds holding Cerus Corp in top ten equity positions was flat from 0 to 0 for the same number . Sold All: 6 Reduced: 25 Increased: 31 New Position: 14.

The company have set target of $55.0000 on Square Inc (SQ) shares. This is 6.88% from the last stock close price. In an analyst note sent to investors and clients on Sunday morning, KeyBanc reconfirmed their Buy rating on shares of SQ.

The stock increased 1.64% or $0.83 during the last trading session, reaching $51.46. About 9.08 million shares traded. Square, Inc. (SQ) has risen 196.00% since April 23, 2017 and is uptrending. It has outperformed by 184.45% the S&P500.

Square, Inc. develops and provides payment processing, point-of-sale , financial, and marketing services worldwide. The company has market cap of $20.40 billion. It provides Square Point of Sale, a POS application software that offers managed payments solutions and advanced software products, including Square Dashboard, a cloud reporting and analytics tool that provides sellers with real-time data and insights about sales, items, customers, and employees; Square Payroll, which empowers sellers to hire, onboard, and pay employees and the associated taxes; and customer engagement tools that help sellers to enhance their business through digital customer feedback, marketing, and loyalty programs. It currently has negative earnings. The firm also offers in-person/card present payments solutions, such as magstripe readers, contactless and chip readers, and chip card readers; and Square Stand that transforms an iPad into a POS terminal.

Among 21 analysts covering Square (SQ), 12 have Buy rating, 2 Sell and 7 Hold. Therefore 57% are positive. Square has $6700 highest and $30.0 lowest target. $49.10’s average target is -4.59% below currents $51.46 stock price. Square had 30 analyst reports since December 11, 2017 according to SRatingsIntel. Wedbush maintained the shares of SQ in report on Wednesday, February 28 with “Hold” rating. The company was maintained on Wednesday, February 28 by Cantor Fitzgerald. The firm has “Buy” rating by RBC Capital Markets given on Friday, February 23. The stock of Square, Inc. (NYSE:SQ) earned “Sell” rating by BTIG Research on Tuesday, February 20. Piper Jaffray maintained the stock with “Hold” rating in Thursday, January 18 report. Evercore maintained it with “Buy” rating and $6700 target in Monday, March 26 report. The firm has “Buy” rating given on Wednesday, February 28 by Needham. Craig Hallum maintained Square, Inc. (NYSE:SQ) on Wednesday, February 28 with “Hold” rating. The rating was initiated by Buckingham Research with “Buy” on Thursday, January 4. Deutsche Bank maintained it with “Buy” rating and $57 target in Friday, March 23 report.

Analysts await Square, Inc. (NYSE:SQ) to report earnings on May, 2 after the close. They expect $-0.04 earnings per share, down 33.33% or $0.01 from last year’s $-0.03 per share. After $-0.03 actual earnings per share reported by Square, Inc. for the previous quarter, Wall Street now forecasts 33.33% negative EPS growth.

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The company has market cap of $711.49 million. The Company’s INTERCEPT Blood System is based on its proprietary technology for controlling biological replication; and targets and inactivates blood-borne pathogens, such as viruses, bacteria, and parasites, as well as harmful white blood cells, while preserving the therapeutic properties of platelet, plasma, and red blood cell transfusion products. It currently has negative earnings. The companyÂ’s INTERCEPT Blood Systems for platelets and plasma are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; and INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion.

The stock decreased 3.00% or $0.17 during the last trading session, reaching $5.49. About 757,926 shares traded. Cerus Corporation (CERS) has risen 26.07% since April 23, 2017 and is uptrending. It has outperformed by 14.52% the S&P500.

Since January 1, 0001, it had 1 insider purchase, and 5 selling transactions for $597,723 activity.

Analysts await Cerus Corporation (NASDAQ:CERS) to report earnings on May, 2. They expect $-0.12 EPS, up 33.33% or $0.06 from last year’s $-0.18 per share. After $-0.10 actual EPS reported by Cerus Corporation for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.

Lesa Sroufe & Co holds 1.51% of its portfolio in Cerus Corporation for 540,752 shares. Elk Creek Partners Llc owns 6.55 million shares or 1.3% of their US portfolio. Moreover, Millrace Asset Group Inc. has 1.28% invested in the company for 395,202 shares. The New York-based Salzhauer Michael has invested 0.54% in the stock. First Midwest Bank Trust Division, a Illinois-based fund reported 784,416 shares.

Cerus Corporation (NASDAQ:CERS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: